AnaptysBio Hits New 12-Month High

Should Investors Buy the Biotech Stock?

Mar. 17, 2026 at 8:19am

Got story updates? Submit your updates here. ›

Shares of AnaptysBio (NASDAQ:ANAB), a clinical-stage biotechnology company focused on immunology and inflammation, reached a new 52-week high of $66.73 on Tuesday. The stock closed at $64.78, with trading volume of 413,489 shares.

Why it matters

AnaptysBio's stock surge comes as the company continues to advance its pipeline of therapeutic antibody candidates, which target various immune-mediated conditions. Investors are closely watching the company's progress, as a successful pipeline could drive significant long-term growth.

The details

Several analysts have recently weighed in on AnaptysBio, with Truist Financial raising its price target from $36 to $50 and Wedbush increasing its price objective from $60 to $75. The company also reported strong Q4 2025 earnings, with revenue of $108.25 million exceeding analyst estimates of $87.09 million.

  • AnaptysBio's stock reached a new 52-week high of $66.73 on Tuesday, March 17, 2026.
  • The company reported Q4 2025 earnings on March 3, 2026.

The players

AnaptysBio, Inc.

A clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation.

Truist Financial

A financial services company that recently raised its price target on AnaptysBio from $36 to $50.

Wedbush

An investment firm that increased its price objective on AnaptysBio from $60 to $75.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.